文献速递痛风与晶体性关节病

秋水仙碱与痛风患者全关节置换术风险的关系:基于人群的队列研究

Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population-Based Cohort Study.
PubMed 文献 · Arthritis Rheumatol · 2026-02-06

该研究基于英国初级保健数据库(2000-2021年),采用新使用者设计、时间分层、倾向评分匹配的队列研究,纳入31,478名秋水仙碱新使用者并与等量非使用者匹配,中位随访4.5年。秋水仙碱使用者全关节置换术风险较非使用者低12%(HR 0.88,95%CI 0.81-0.96),在合并膝/髋骨关节炎的痛风患者中风险低23%(HR 0.77,95%CI 0.64-0.92)。

要点

  • 秋水仙碱使用者全关节置换术风险较非使用者低12%(HR 0.88,95%CI 0.81-0.96)。
  • 合并膝/髋骨关节炎的痛风患者中,秋水仙碱使用者全关节置换术风险低23%(HR 0.77,95%CI 0.64-0.92)。
  • 秋水仙碱可能对痛风合并膝或髋骨关节炎患者降低关节置换术风险具有长期获益。

核心结论

  • 在大型痛风人群队列中,秋水仙碱起始治疗与全关节置换术风险适度降低相关。
  • 秋水仙碱可能对痛风合并膝或髋骨关节炎患者降低关节置换术风险具有长期获益。

研究设计与样本

  • 新使用者设计、时间分层、基于人群的队列研究,使用英国初级保健数据库(2000-2021年)。
  • 识别痛风诊断后新处方秋水仙碱的参与者,每位秋水仙碱起始者通过一年队列累积区块与一名非起始者进行倾向评分匹配。
  • 采用Cox比例风险回归评估秋水仙碱对全关节置换术风险的影响,并重复分析限于痛风合并膝/髋骨关节炎的参与者。

主要发现

  • 识别31,478名秋水仙碱起始者,与等量非起始者进行倾向评分匹配,平均年龄60岁,平均体重指数30,中位随访时间4.5年。
  • 秋水仙碱起始者全关节置换术风险较非起始者低12%(HR 0.88,95%CI 0.81-0.96),额外校正混杂因素后结果相似(HR 0.89,95%CI 0.82-0.97)。
  • 合并膝/髋骨关节炎的痛风患者中,秋水仙碱起始者全关节置换术风险较非起始者低23%(HR 0.77,95%CI 0.64-0.92)。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the relation of colchicine use to the risk of total joint arthroplasty (TJA) in individuals with gout, the most common form of arthritis for which colchicine is prescribed. METHODS: This new-user design, time-stratified, population-based cohort study used a UK primary care database (2000-2021). We identified participants with gout who were newly prescribed colchicine after their gout diagnosis. Each colchicine initiator was propensity score matched with a noninitiator using one-year cohort accrual blocks. The effect of colchicine on the risk of TJA was assessed using Cox proportional hazard regression. Analyses were repeated and limited to participants with both gout and knee/hip osteoarthritis (OA). RESULTS: We identified 31,478 colchicine initiators who were propensity score matched to an equal number of noninitiators (mean age 60 years, mean body mass index 30), with a median follow-up time of 4.5 years. Colchicine initiators had a 12% lower risk of TJA than noninitiators (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.81-0.96), which remained similar after additional adjustment for confounders (HR 0.89, 95% CI 0.82-0.97). Colchicine initiators with gout had a 23% lower risk of TJA among those with knee/hip OA (HR 0.77, 95% CI 0.64-0.92) compared with noninitiators (HR 0.77, 95% CI 0.64-0.92). CONCLUSION: In this large population-based cohort of people with gout, colchicine initiation was associated with a modestly lower risk of TJA. Colchicine may offer a long-term benefit in reducing the risk of joint arthroplasty in individuals with gout and knee or hip OA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Tilley S, Peloquin C, et al. Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population-Based Cohort Study. Arthritis Rheumatol. 2026. PMID: 41235723. doi:10.1002/art.43441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。